Abstract
Background Apolipoprotein E-ε4 (APOE ε4) genotype may be associated with the development of cognitive decline in idiopathic Parkinson’s disease i(PD), however its effect in genetic PD is understudied.
Objectives In the current work we aimed to assess the impact of APOE genotype on cognition in iPD as well as in genetic PD with mutations in the Alpha-synuclein (SNCA) and Glycocerebrosidase (GBA1) genes.
Methods Two independent PD cohorts were analyzed: The first cohort (Athens) included 50 iPD patients, 35 patients with the p.A53T SNCA mutation and 59 patients with GBA1 mutations (13 mild /46 severe). The second cohort (Tübingen) included 292 patients with GBA1 mutations (170 risk/ 52 mild/ 70 severe). All patients underwent cognitive testing and were genotyped for APOE.
Results In the iPD subgroup, carriers of at least one APOE ε4 exhibited lower Montreal Cognitive Assessment test (MoCA) score as compared to non-carriers (p=0.044). Notably, in the p.A53T SNCA subgroup, APOE ε4 carriers also had lower MoCA scores compared to non-carriers (p=0.039). There were no APOE ε4-related differences in the two GBA1 subgroups (Athens, p=0.729; Tübingen p=0.585).
Conclusions We confirm the impact of APOE ε4 on cognitive decline in iPD and for the first time report a similar effect in p.A53T SNCA mutation carriers, who represent the prototypical genetic synucleinopathy. Contrary, the lack of such an effect in two independent cohorts of GBA1 mutation carriers, who are thought to also manifest a predominant alpha-synuclein-driven cognitive decline, suggests differences in factors associated with cognitive dysfunction between different genetic forms of synucleinopathies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially funded by the National Network for Neurodegenerative Diseases (ΕΔΙΑΝ) (GSRT).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Eginition Hospital Ethics Committee Ethical Aproval was granted by the EC for the conduction of the study as a part of Thalis Parkinson's disease database
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosure/Conflict of Interest Christos Koros received funding from the Michael J Fox Foundation for his participation in PPMI.
Kathrin Brockmann is employed at the University of Tuebingen and served as Consultancy and Advisory Board in Hoffmann La Roche. She has received honoraria as a Speaker from UCB and ABBVie and a Grant from the MJFF.
Athina Simitsi received funding from the Michael J Fox Foundation for her participation in PPMI and from “ALAMEDA” study (H2020-EU, Grant Agreement 101017558.
Anastasia Bougea received funding from “ALAMEDA” study (H2020-EU, Grant Agreement 101017558.
Hui Liu has no disclosures.
Ann-Kathrin Hauser has no disclosures.
Claudia Schulte has no disclosures.
Stefanie Lerche has no disclosures.
Ioanna Pachi has no disclosures.
Nikolaos Papagiannakis has no disclosures.
Roubina Antonelou has no disclosures.
Athina Zahou has no disclosures.
Isabel Wurster has no disclosures.
Efthymia Efthymiopoulou received funding from the Michael J Fox Foundation for her participation in PPMI.
Ion Beratis received funding from the Michael J Fox Foundation for his participation in PPMI.
Matina Maniati has no disclosures.
Marina Moraitou has no disclosures.
Helen Michelakakis has no disclosures.
Georgios Paraskevas has no disclosures.
Sokratis G. Papageorgiou has no disclosures.
Constantin Potagas has no disclosures.
Dimitra Papadimitriou has no disclosures.
Maria Bozi has no disclosures.
Maria Stamelou, serves on the editorial boards of Movement Disorders Journal and Frontiers in Movement Disorders and has received research support from the Michael J Fox Foundation (PPMI).
Thomas Gasser has received a grant from Bundesministerium für Bildung und Forschung (BMBF) Heinemannstrasse 2 und 6, 53170 Bonn. Moreover he has received funding from Deutsche Forschungsgemeinschaft (DFG), from the Ministry for Science, Research and Art Baden-Württemberg (MWK) and from The Michael J. Fox Foundation for Parkinson’s Research (Steering Committee Member Award). Prof. Gasser has received speakers honoraria from UCB Pharma, Novartis, Teva and MedUpdate. He is chairman of the scientific advisory board of the “Joint Programming for Neurodegenerative Diseases” program, funded by the European Commission.
Leonidas Stefanis over the past year has received the following grants : PPMI2 (supported by the Michael J. Fox Foundation), IMPRIND-IMI2 Number 116060 (EU, H2020), “Transferring autonomous and non-autonomous cell degeneration 3D models between EU and USA for development of effective therapies for neurodegenerative diseases (ND) - CROSS NEUROD” (H2020-EU 1.3.3., Grant Number778003), «Chaperone-Mediated Autophagy in Neurodegeneration» (Hellenic Foundation for Research and Innovation Grant HFRI-FM17-3013), “ALAMEDA” (H2020-EU, Grant Agreement 101017558), “Next-generation antisense molecules for Parkinson’s disease therapy (THERASYN)” (Greek Secretariat of Research and Technology (GSRT), Collaborator), “National Network for Neurodegenerative Diseases (EΔIAN)” (GSRT), and “CMA as a Means to Counteract alpha-Synuclein Pathology in Non-Human Primates” (by the Michael J. Fox Foundation (Collaborator)). He has served on Advisory Boards for Abbvie, ITF Hellas and Biogen and has received honoraria from Abbvie and Sanofi. There are no specific disclosures related to the current work.
Funding: This study was partially funded by the “National Network for Neurodegenerative Diseases (EΔIAN)” (GSRT).
Data Availability
All data produced in the present study are available upon reasonable request to the authors
